| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5857408 | Regulatory Toxicology and Pharmacology | 2012 | 8 Pages |
Abstract
⺠The safety and toxicology of Lactobacillus reuteri NCIMB 30242 supplement was investigated. ⺠The study includes 131 randomized subjects receiving supplement or placebo capsules. ⺠No clinically significant differences in blood chemistry/hematology were observed. ⺠The adverse events and safety parameters were found to be similar in treatment and placebo groups. ⺠Results demonstrate that 2.9 Ã 109 CFU twice a day dose of L. reuteri NCIMB 30242 supplement is safe.
Keywords
Lactobacillus reuteriCSVWBCsBSHSOPGGTQPSRBCsALKPALTRed blood cellsCa2+Cl−Na+LABASTAspartate aminotransferasealanine transaminaseAlkaline phosphataseSafetyLactic acid bacteriabpmANOVAone-way analysis of variancenumber of subjectsStandard operating proceduresSodiumToxicologybody mass indexBMIbeats per minuteAdverse eventsPhosphateSupplementpatient-reported outcomePROBile salt hydrolasePotassiumProbioticqualified presumption of safetyAPAChloridecholesterolCalciumquality controlgamma-glutamyl transpeptidasewhite blood cells
Related Topics
Life Sciences
Environmental Science
Health, Toxicology and Mutagenesis
Authors
Mitchell L. Jones, Christopher J. Martoni, E. Di Pietro, Ryan R. Simon, Satya Prakash,